India · Delayed Price · Currency is INR Jagsonpal Pharmaceuticals Statistics
Total Valuation
NSE:JAGSNPHARM has a market cap or net worth of INR 14.11 billion. The enterprise value is 13.13 billion.
| Market Cap | 14.11B |
| Enterprise Value | 13.13B |
Important Dates
The last earnings date was Monday, April 27, 2026.
| Earnings Date | Apr 27, 2026 |
| Ex-Dividend Date | Sep 12, 2025 |
Share Statistics
NSE:JAGSNPHARM has 67.14 million shares outstanding. The number of shares has increased by 1.40% in one year.
| Current Share Class | 67.14M |
| Shares Outstanding | 67.14M |
| Shares Change (YoY) | +1.40% |
| Shares Change (QoQ) | +9.11% |
| Owned by Insiders (%) | 11.34% |
| Owned by Institutions (%) | 1.44% |
| Float | 16.55M |
Valuation Ratios
The trailing PE ratio is 33.29.
| PE Ratio | 33.29 |
| Forward PE | n/a |
| PS Ratio | 4.91 |
| PB Ratio | 5.11 |
| P/TBV Ratio | 7.12 |
| P/FCF Ratio | 30.23 |
| P/OCF Ratio | 30.13 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 22.60, with an EV/FCF ratio of 28.13.
| EV / Earnings | 30.47 |
| EV / Sales | 4.57 |
| EV / EBITDA | 22.60 |
| EV / EBIT | 26.99 |
| EV / FCF | 28.13 |
Financial Position
The company has a current ratio of 5.06, with a Debt / Equity ratio of 0.03.
| Current Ratio | 5.06 |
| Quick Ratio | 4.36 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | 0.14 |
| Debt / FCF | 0.17 |
| Interest Coverage | 47.31 |
Financial Efficiency
Return on equity (ROE) is 16.69% and return on invested capital (ROIC) is 25.96%.
| Return on Equity (ROE) | 16.69% |
| Return on Assets (ROA) | 10.22% |
| Return on Invested Capital (ROIC) | 25.96% |
| Return on Capital Employed (ROCE) | 16.86% |
| Weighted Average Cost of Capital (WACC) | 2.41% |
| Revenue Per Employee | 2.05M |
| Profits Per Employee | 307,949 |
| Employee Count | 1,399 |
| Asset Turnover | 0.97 |
| Inventory Turnover | 6.99 |
Taxes
In the past 12 months, NSE:JAGSNPHARM has paid 144.36 million in taxes.
| Income Tax | 144.36M |
| Effective Tax Rate | 25.10% |
Stock Price Statistics
The stock price has increased by +3.56% in the last 52 weeks. The beta is -0.34, so NSE:JAGSNPHARM's price volatility has been lower than the market average.
| Beta (5Y) | -0.34 |
| 52-Week Price Change | +3.56% |
| 50-Day Moving Average | 189.17 |
| 200-Day Moving Average | 209.08 |
| Relative Strength Index (RSI) | 62.79 |
| Average Volume (20 Days) | 225,823 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, NSE:JAGSNPHARM had revenue of INR 2.87 billion and earned 430.82 million in profits. Earnings per share was 6.31.
| Revenue | 2.87B |
| Gross Profit | 1.83B |
| Operating Income | 486.30M |
| Pretax Income | 575.18M |
| Net Income | 430.82M |
| EBITDA | 580.74M |
| EBIT | 486.30M |
| Earnings Per Share (EPS) | 6.31 |
Balance Sheet
The company has 1.06 billion in cash and 81.65 million in debt, with a net cash position of 979.55 million or 14.59 per share.
| Cash & Cash Equivalents | 1.06B |
| Total Debt | 81.65M |
| Net Cash | 979.55M |
| Net Cash Per Share | 14.59 |
| Equity (Book Value) | 2.76B |
| Book Value Per Share | 39.40 |
| Working Capital | 1.15B |
Cash Flow
In the last 12 months, operating cash flow was 468.12 million and capital expenditures -1.48 million, giving a free cash flow of 466.64 million.
| Operating Cash Flow | 468.12M |
| Capital Expenditures | -1.48M |
| Depreciation & Amortization | 94.44M |
| Net Borrowing | -12.21M |
| Free Cash Flow | 466.64M |
| FCF Per Share | 6.95 |
Margins
Gross margin is 63.66%, with operating and profit margins of 16.93% and 15.00%.
| Gross Margin | 63.66% |
| Operating Margin | 16.93% |
| Pretax Margin | 20.03% |
| Profit Margin | 15.00% |
| EBITDA Margin | 20.22% |
| EBIT Margin | 16.93% |
| FCF Margin | 16.25% |
Dividends & Yields
This stock pays an annual dividend of 4.00, which amounts to a dividend yield of 1.84%.
| Dividend Per Share | 4.00 |
| Dividend Yield | 1.84% |
| Dividend Growth (YoY) | 25.00% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 38.67% |
| Buyback Yield | -1.40% |
| Shareholder Yield | 0.44% |
| Earnings Yield | 3.05% |
| FCF Yield | 3.31% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on January 8, 2025. It was a forward split with a ratio of 2.5.
| Last Split Date | Jan 8, 2025 |
| Split Type | Forward |
| Split Ratio | 2.5 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 4 |